Personalized ceftobiprole dosing for older adults
Part of Infections clinical trials.
This study tests whether tailoring the dose of the antibiotic ceftobiprole based on your individual body and kidney function helps treat infections more safely and effectively in older adults.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 60 years old.
- You will be receiving ceftobiprole (an antibiotic) for more than 5 days.
- You cannot have used ceftobiprole in the month before the study starts.
- You must not be on dialysis or have severe kidney problems (like kidney failure, a single kidney, or a kidney transplant).
- Your body mass index (BMI) must be less than 30.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized way of giving a strong antibiotic (ceftazidime-avibactam) to older adults. Doctors adjust the dose based on your own body's handling of the drug, aiming to make treatment safer and more effective.
This study looks at how best to dose certain antibiotics in people age 75 and older who are admitted to a geriatric (older-adult) hospital unit. It aims to measure antibiotic levels in the body to see whether dosing can be improved for older patients.
This study tests a personalized approach to treat and prevent recurring urinary tract infections (UTIs) in women aged 65 and older. It aims to find the best way to manage symptoms and reduce future infections.
This trial tests a new antibiotic called ceftibuten-ledaborbactam in healthy volunteers to see if it is safe and how the body processes it. You may join if you are a healthy adult and do not have allergies to certain antibiotics.
This trial tests if adjusting ceftazidime (a powerful antibiotic) early on helps treat serious infections better in intensive care patients. You may qualify if you are in the ICU and your doctor is considering starting this antibiotic.
This study tests a precise dosing approach for the antibiotic ceftazidime-avibactam to treat serious infections in ICU patients. It aims to help people with hard-to-treat bacteria that are resistant to many other antibiotics.
Hear when a new Ceftobiprole trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.